Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants

Journal of Korean Medical Science

Volumn 23, Issue 6, 2008, Pages 929-936

  Kim, Kyung Hyo ^a   Lee, Hyunju ^a   Chung, Eun Hee ^b   Kang, Jin Han ^c   Kim, Jong Hyun ^c   Kim, Jung Soo ^d   Lee, Hoan Jong ^e   Oh, Sung Hee ^f   Park, Eun Ae ^a   Park, Su Eun ^g  

^a Ewha Womans University School of Medicine   (South Korea)

^b Dankook University College of Medicine   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Chonbuk National University Medical School   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

^f Hanyang University College of Medicine   (South Korea)

^g Pusan National University School of Medicine   (South Korea)

Author keywords

Haemophilus; Immunogenicity; Safety; Vaccines

Indexed keywords

BACTERIAL POLYSACCHARIDE; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE TETANUS TOXIN CONJUGATE; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE-TETANUS TOXIN CONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE-TYPE B POLYSACCHARIDE-NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; HAEMOPHILUS VACCINE; OUTER MEMBRANE PROTEIN; TETANUS TOXOID;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOLOGY; INFANT; KOREA; MULTICENTER STUDY;

BACTERIAL OUTER MEMBRANE PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; KOREA; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID;

EID: 60549105919     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.6.929     Document Type: Article

References (33)

1. Wenger JD, Ward JI. Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein WA. Vaccines. 4th ed. Philadelphia: WB Saunders Co 2004; 229-68.
2. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003; 143 (6 Suppl): S163-87.
3. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b disease among infants and children--United States, 1987-1995. MMWR Morb Mortal Wkly Rep 1996; 45: 901-6.
4. Losonsky GA, Santosham M, Sehgal VM, Zwahlen A, Moxon ER. Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population. Pediatr Infect Dis 1984; 3: 539-47.
5. Ward JI, Margolis HS, Lum MK, Fraser DW, Bender TR, Anderson P. Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet 1981; 1: 1281-5.
6. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120: 184-9.
7. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17 (9 Suppl): S117-22.
8. Siber GR, Santosham M, Reid GR, Thompson C, Almeido-Hill J, Morell A, deLange G, Ketcham JK, Callahan EH. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990; 323: 1387-92.
9. Santosham M, Rivin B, Wolff M, Reid R, Newcomer W, Letson GW, Almeido-Hill J, Thompson C, Siber GR. Prevention of Haemophilus influenzae type b infections in Apache and Navajo children. J Infect Dis 1992; 165 (Suppl 1): S144-51.
10. Rossi IA, Zuber PL, Dumolard L, Walker DG, Watt J. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine 2007; 25: 7075-80.
11. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide- human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990; 135: 121-8.
12. Kim KH, Lim SY. Validation of enzyme immunoassay for the quantitative measurement of human IgG antibodies specific for Haemophilus influenzae type b capsular polysaccharide. Korean J Pediatr 2007; 50: 143-50.
13. Romero-Steiner S, Spear W, Brown N, Holder P, Hennessy T, Gomez De Leon P, Carlone GM. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin Diagn Lab Immunol 2004; 11: 89-93.
14. Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992; 267: 1489-94.
15. Choi SY, Kim HT, Kim YW, Kang YJ, Chung YC, Chang JK, Lee HJ. Immunogenicity of Haemophilus influenzae PRP-D conjugate vaccine in Korean infants. J Korean Pediatr Soc 1999; 42: 771-7.
16. TM) in Korean infants. Korean J Pediatr Infect Dis 2003; 10: 71-9.
17. Kim JS, Cho SB, Lee HR, Park SK, Hwang PH. Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) in Korean infants. Korean J Infect Dis 1996; 28: 225-32.
18. Yang PS, Seo JI, Noh KT, Yoo JH, Hwang KS, Hwang KG. Studies of the change of antibody titers after vaccination of Haemophilus influenzae PRP-T conjugate vaccine. J Korean Pediatr Soc 2002; 45: 987-93.
19. Yoo ES, Park EA, Kim GH. Natural anti-PRP antibody levels of Haemophilus influenzae type b (Hib) and changes of antibody levels after three doses of vaccination. J Korean Pediatr Soc 1995; 38: 1201-9.
20. Kayhty H, Eskola J, Peltola H, Ronnberg PR, Kela E, Karanko V, Saarinen L. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991; 145: 223-7.
21. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992; 121: 355-62.
22. Kayhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22: 397-402.
23. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100.
24. World Health Organization. WHO Expert Committee on Biological Standardization. Forty-ninth report. World Health Organ Tech Rep Ser 2000; 897: i-vi, 1-106.
25. Peltola H, Aavitsland P, Hansen KG, Jonsdottir KE, Nokleby H, Romanus V. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999; 179: 223-9.
26. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302-17.
27. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998; 351: 1472-6.
28. Kim JS, Jang YT, Kim JD, Park TH, Park JM, Kilgore PE, Kennedy WA, Park E, Nyambat B, Kim DR, Hwang PH, Kim SJ, Eun SH, Lee HS, Cho JH, Kim YS, Chang SJ, Huang HF, Clemens JD, Ward JI. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine 2004; 22: 3952-62.
29. Nottidge VA. Haemophilus influenzae meningitis: a 5-year study in Ibadan, Nigeria. J Infect 1985; 11: 109-17.
30. Schoendorf KC, Adams WG, Kiely JL, Wenger JD. National trends in Haemophilus influenzae meningitis mortality and hospitalisation among children, 1980 through 1991. Pediatrics 1994; 93: 663-8.
31. Levine OS, Schwartz B, Pierce N, Kane M. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J 1998; 17 (9 Suppl): S95-113.
32. Heath PT, Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child 1997; 77: 488-92.
33. Rushdy A, Ramsay M, Heath PT, Azzopardi HJ, Slack MP. Infant Hib vaccination and herd immunity. J Pediatr 1999; 134: 253-4.